Non Small Cell Lung Cancer Clinical Trials in Scottsdale, Arizona

10 studies are recruiting for non small cell lung cancer in Scottsdale, Arizona right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Dabrafenib and/or Trametinib Rollover Study

   This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the requirements for the primary objective, and who are judged by…

   Stage

   Phase 4

   Ages

   18 to 100

   Site

   Honor Health Research Institute, Scottsdale, Arizona

   Locations

   34 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT03340506 on ClinicalTrials.gov

2. A Study of KK2269 in Adult Participants With Solid Tumors

   This is a first-in-human study of KK2269. Part 1 and Part 2 will be conducted as a multicenter, open-label, non-randomized, dose-escalation study. Participants with advanced or metastatic solid tumors for which no standard therapy is available will be enrolled in Part 1. In Part 1, the primary obje…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic Arizona, Scottsdale, Arizona

   Locations

   32 in total

   Run by

   Kyowa Kirin Co., Ltd.

   See if you can join NCT06266299 on ClinicalTrials.gov

3. A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

   This is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4255 in adult participants with advanced solid tumors with ERBB2 alterations or HER2 overexpr…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   HonorHealth Research Institute, Scottsdale, Arizona

   Locations

   15 in total

   Run by

   Cogent Biosciences, Inc.

   See if you can join NCT07361562 on ClinicalTrials.gov

4. Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

   This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-small cell lung cancer (NSCLC) that is either locally advanced…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Ironwood Cancer & Research Centers, Scottsdale, Arizona

   Locations

   440 in total

   Run by

   Pfizer

   See if you can join NCT07222566 on ClinicalTrials.gov

5. AOH1996 for the Treatment of Refractory Solid Tumors

   This phase I trial studies the side effects and best dose of AOH1996 in treating patients with solid tumors that do not respond to treatment (refractory). AOH1996 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Honor Health Research and Innovation Institute, Scottsdale, Arizona

   Locations

   3 in total

   Run by

   City of Hope Medical Center

   See if you can join NCT05227326 on ClinicalTrials.gov

6. Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

   This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tum…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic Scottsdale, Scottsdale, Arizona

   Locations

   15 in total

   Run by

   Tango Therapeutics, Inc.

   See if you can join NCT06810544 on ClinicalTrials.gov

7. A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

   The goal of this Open-Label Study is to evaluate the safety and tolerability of PRTH-101 alone or in combination with pembrolizumab in adults with advance or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Honor Health Research Institute, Scottsdale, Arizona

   Locations

   11 in total

   Run by

   Incendia Therapeutics

   See if you can join NCT05753722 on ClinicalTrials.gov

8. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

   International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

   Stage

   Not phased

   Ages

   Any age

   Site

   Massive Bio SYNERGY-AI site, Scottsdale, Arizona

   Locations

   68 in total

   Run by

   Massive Bio, Inc.

   See if you can join NCT03452774 on ClinicalTrials.gov

9. Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

   This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab [Gazyva®] pre-treatment, by IV infusion, and in combination with pembrolizumab. A Phase 2 monotherapy arm is also planned;…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   HonorHealth Research Institute, Scottsdale, Arizona

   Locations

   6 in total

   Run by

   Simcha IL-18, Inc.

   See if you can join NCT04787042 on ClinicalTrials.gov

10. Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

    This clinical study is an open-label, Phase 1, dose-escalation study to determine the safety, tolerability, and efficacy of the drug product produced by Administering CRX100 alone and in combination with Pembrolizumab in advanced solid malignancies. Patients will be screened and evaluated to determ…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    HonorHealth Research Institute, Scottsdale, Arizona

    Locations

    3 in total

    Run by

    BioEclipse Therapeutics

    See if you can join NCT04282044 on ClinicalTrials.gov